FMO2 ameliorates nonalcoholic fatty liver disease by suppressing ER-to-Golgi transport of SREBP1.
Ke C, Xiao C, Li J, Wu X, Zhang Y, Chen Y, Sheng S, Fu Z, Wang L, Ni C, Zhao J, Shi Y, Wu Y, Zhong Z, Nan J, Zhu W, Chen J, Wu R, Hu X.
Ke C, et al. Among authors: wu y, wu x, wu r.
Hepatology. 2023 Oct 24. doi: 10.1097/HEP.0000000000000643. Online ahead of print.
Hepatology. 2023.
PMID: 37874228